News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celladon Corporation Announces Pricing Of Initial Public Offering


1/30/2014 8:53:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, announced today the pricing of its initial public offering of 5,500,000 shares of its common stock at $8.00 per share. Celladon has also granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock to cover overallotments, if any. All shares of the common stock in the offering are being sold by Celladon. Celladon's common stock is scheduled to begin trading on The NASDAQ Global Market on January 30, 2014 under the symbol "CLDN." The offering is scheduled to close on February 4, 2014, subject to customary closing conditions.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES